| INTRODUC TI ON
Patients with cirrhosis are vulnerable to developing physical frailty that results from muscle wasting and undernutrition-2 conditions that are nearly inseparable from the state of cirrhosis itself. 1, 2 In theory, liver transplantation should reverse these conditions and therefore, reverse physical frailty. However, no objective data exist on the extent to which-or how rapidly-physical frailty improves after liver transplantation. Such information is crucial to informing discussions with patients and caregivers about what to expect after liver transplantation and guiding prognosis regarding quality of life.
One of the major barriers to investigating recovery from physical frailty after liver transplantation has been the frailty measurement tools themselves. 3 While several studies have investigated frailty 1, 4 or aspects of frailty (eg, cardiopulmonary fitness, 5, 6 disability, 7, 8 Frailty is prevalent in liver transplant candidates, but little is known of what happens to frailty after liver transplantation. We analyzed data for 214 adult liver transplant recipients who had ≥1 frailty assessment using the Liver Frailty Index (LFI) at 3-(n = 178), 6-(n = 139), or 12-(n = 107) months posttransplant (higher values=more frail). "Frail" and "robust" were defined as LFI ≥4.5 and <3.2. Median pre-liver transplant LFI was 3.7, and was worse at 3 months (3.9; P = .02), similar at 6 months (3.7; P = .07), and improved at 12 months (3.4; P < .001). The percentage who were robust pre-and 3-, 6-, and 12-months posttransplant were 25%, 14%, 28%, and 37%; the percentage frail were 21%, 21%, 10%, and 7%. In univariable analysis, each 0.1 pretransplant LFI point more frail was associated with a decreased odds of being robust 
K E Y W O R D S
clinical research/practice, comorbidities, geriatrics, liver transplantation/hepatology, nutrition, patient characteristics, quality of life (QOL), rehabilitation subtle changes over time; cardiopulmonary exercise testing is technically challenging to administer, limiting the number of patients who are able to undergo repeat posttransplant testing.
Recently, we developed the Liver Frailty Index, a tool comprising 3 easily administered tests-grip strength, chair stands, and balance testing-specifically to measure physical frailty in patients with cirrhosis awaiting liver transplantation. 9 It has advantages over other frailty assessment tools that have been studied in cirrhotic patients in that it is entirely performance-based, is scored on a continuous scale (making it suitable for investigating longitudinal changes in frailty posttransplant), and perhaps most importantly, is directed towards dimensions of frailty-malnutrition, muscle wasting, and neuromotor coordination-that are most likely to be impacted by end-stage liver disease.
Armed with this Liver Frailty Index as our objective frailty assessment tool, we aimed to investigate physical frailty after liver transplantation.
| ME THODS

| Patient population
We analyzed data from the Functional Assessment in Liver Transplantation (FrAILT) Study; the FrAILT Study protocol has been published. 9 Briefly, patients with cirrhosis who were listed and active for liver transplantation at the University of California, San 
| Study procedures: Measurements of frailty
All patients underwent objective measurement of frailty using the following:
1. Grip strength 11 : the average of 3 trials in the subject's dominant hand using a hand dynamometer, measured in kilograms;
2. Timed chair stands 12 : measured as the number of seconds it takes to do 5 chair stands with the subject's arms folded across the chest;
3. Balance testing 12 : measured as the number of seconds that the subject can balance in 3 positions (feet placed side-to-side, semitandem, and tandem) for a maximum of 10 seconds each.
These 3 tests were administered by trained study personnel. The Liver Frailty Index was calculated from these 3 tests using the following equation 12 (calculator available at: http://liverfrailtyindex.ucsf.edu):
For classifications of frailty, we used previously established cutoffs of the Liver Frailty Index to define "robust" (<3.2), "pre-frail" (between 3.2 and <4.5), and "frail" (≥4.5). 9 These cut-offs were selected based on 20th percentile and 80th percentile cut-offs for the Liver Frailty Index in our initial development cohort. 9 As a point of clinical reference, the median Liver Frailty Index score of a liver transplant candidate with well-compensated cirrhosis and hepatocellular carcinoma is 3.16, which would be classified as robust.
| Timing of frailty measurements
Measurements of frailty occurred both before and after liver transplantation in the outpatient clinic setting:
1.
Pretransplant. Due to the unpredictable timing of liver transplantation, patients underwent frailty measurements at every outpatient clinic visit as part of the FrAILT Study. For this particular article, the measurement closest to the date of transplant was used as the "pretransplant" measurement for our analyses.
2.
Posttransplant. Patients underwent repeat measurements of frailty after liver transplantation for up to 1 year. Measurements taken at 3, 6, and 12 months after the date of transplant (±1 month) were used as the posttransplant assessments for our analyses.
| Additional data collection
Demographic data were extracted from the electronic health re- recipients are also required to notify our center of any hospitalization upon admission, facilitating complete data capture of hospitalizations.
| Statistical analysis
Characteristics were compared between robust, pre-frail, and frail patients using χ 2 or Wilcoxon/Kruskal-Wallis tests for categorical and continuous variables, respectively. Liver Frailty Index scores were reported using medians, interquartile ranges (IQR), and standard errors and compared between pre-and posttransplant periods by
Wilcoxon signed rank tests to account for paired differences. Logistic regression assessed the odds of being robust at 3-, 6-, and 12-months posttransplant associated with the pretransplant Liver Frailty Index in univariable analysis and then adjusted for covariables that were biologically plausibly associated with frailty, including laboratory characteristics of the entire cohort are listed in Table 1 . Median age was 62 years, 36% were female, 59% were non-Hispanic white, 54%
had chronic hepatitis C as their cause of liver disease, and 45% had hepatocellular carcinoma (HCC 
| Posttransplant frailty measurements (Figure 1)
Posttransplant frailty measurements were available for 178 recipients at 3 months, 135 recipients at 6 months, and 107 recipients at 12 months. There were no statistically significant differences in the number of posttransplant assessments by pretransplant frailty category (frail, pre-frail, robust; P = .30). Pretransplant, median
Liver Frailty Index was 3.7 (IQR 3.2-4.3; standard error ± 0.06). 
| Changes in posttransplant frailty measurements
At 3-, 6-, and 12-months posttransplant, median changes in Liver
Frailty Index score were 0.09, -0.04, and -0.28 (where a positive value indicates worsening of frailty status). Compared to pretransplant, 59%, 41%, and 32% experienced worsening of their Liver
Frailty Index score at 3, 6, and 12 months, respectively. (Table 2 ). This association remained nearly unchanged even after adjustment for covariables that might be associated with frailty status, including laboratory MELD score at transplant, recipient age, female sex, and diabetes (Table 3) . Donor factors-including donor age, donation after cardiac death, or living donor liver transplantation-were not associated with the odds of being robust posttransplant (P > .05). (Table 4) For the entire cohort, median (IQR) length of stay for the transplant hospitalization was 7 days (6-11) and the number of days in the ICU was 2 days
(1-3). The median (IQR) number of readmission inpatient days within the first 3 months after transplantation was 5 days (3-10). Patients who were frail pretransplant experienced significantly higher transplant length of stay compared to nonfrail patients (9 vs 7 days; P = .004) and hospitalized days within 3 months of transplant (2 vs 0 days; P = .03). There was a trend toward greater ICU days among the frail versus nonfrail patients (3 vs 2 days; P = .06). The proportion of patients who were discharged to an institution after their acute stay (eg, rehabilitation facility, skilled nursing home) was similar in frail versus nonfrail patients (9% vs 4%; P = . 19 ).
There was a trend toward a greater median number of hospitalized days during the 3-to 6-month time period following liver transplantation between frail versus nonfrail patients (3 vs 0 days; P = .08), but no significant difference in hospitalized days during the 6-12-month posttransplant time period. Rates of death within 12 months posttransplant were similar between frail and nonfrail patients (2% vs 2%; P = .94). There was a strong trend toward increased rates of death overall among frail versus nonfrail patients (11% vs. 4%; P = .06).
| D ISCUSS I ON
Care of patients with cirrhosis awaiting liver transplantation has traditionally focused on management of portal hypertensive manifestations (eg, ascites, hepatic encephalopathy, and gastroesophageal The patients in the white boxes did not experience any change in their frailty category 12-mo posttransplant. The patients in the dark gray-shaded boxes experienced improvement in their frailty status after LT; the patients in the light gray-shaded boxes experienced worsening of their frailty status 12 mo after LT. Perhaps more importantly, fewer than 40% of liver transplant recipients achieved "robustness" by 1 year. Of these individuals who were robust at 1 year, two thirds were already robust, and one third were pre-frail prior to liver transplantation. The association between pretransplant frailty status and posttransplant frailty status was statistically significant, and the magnitude of the effect clinically substantial, which persisted despite adjustment for a number of pretransplant variables that we believed might impact the posttransplant frailty phenotype.
TA B L E 3
In order to understand these data from the patients' perspective, we offer additional information to interpret the actual values of the Liver Frailty Index. The median Liver Frailty Index score for patients listed with HCC and a low Model for End-Stage Liver Disease-Sodium score (which we set at ≤12) in this cohort-whom we believed were the "healthiest" patients based on our clinical experience-was 3.16 (95% confidence interval, 2.79-3.51).
Furthermore, in a small sample of healthy community-dwelling adults with a mean age of 59 years, close to the age of our cohort, average Liver Frailty Index score was 2.4. Therefore, we believe that the cut-point of 3.2 that we used to define "robust" is a reasonable cut-point that is consistent with the level of physical function that patients would desire to achieve after liver transplantation.
Using a distribution-based method to establish clinically important with heart failure, nearly all (n = 12) experienced reversal of their frailty after heart transplantation at a median of 6 months after surgery, although data regarding the extent of their improvement (ie, whether they became robust) are lacking. 18 While kidney and heart transplant surgery may be associated with less morbidity than liver transplant surgery, our data in liver transplant recipients stand in stark contrast to these other solid organ transplant recipients, highlighting the need for organ-specific efforts to improve frailty both pre-and posttransplantation.
There are undoubtedly a number of factors that contribute to persistent frailty after liver transplantation. Pretransplant frailty results from not only cirrhosis itself, but also from age-and Although quantifying the contribution of each of these factors is beyond the scope of this initial descriptive study, they represent important avenues for future research.
Before we discuss the clinical implications of these data, it is important for us to acknowledge the limitations of this study. So how can we incorporate these data into our clinical practice?
First, it is important to point out that we measured pretransplant physical frailty in the outpatient setting. As such, these data may not be applicable to those initially evaluated in the inpatient setting.
However, this was intentional, as we aimed to capture the patients'
underlying physiologic reserve, which may not reverse after liver transplantation, rather than simply the effects of acute hepatic decompensation that are more likely to substantially and rapidly reverse with a new liver, as we have previously conceptualized. 26 This allows the opportunity for greater impact on patient care, through 2 specific ways:
1. Inform. These data are critical to setting reasonable expectations for our patients and their caregivers regarding the timing and degree of physical recovery after liver transplantation. what we in the transplant community-and our patients-hope to achieve with liver transplantation. Is the goal to "return to normal function," or is it enough that liver transplant recipients are no longer frail? At the very least, our data provide strong motivation to establish programs dedicated not only to prehabilitating patients prior to liver transplantation but also engaging patients through interventions aimed at accelerating physical recovery afterwards.
The next critical step is to integrate a metrics of frailty in liver transplant practice, laying the foundation for future frailty-focused interventions. 
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